Colorectal cancer (CRC) remains the third leading cause of cancer-related deaths in the United States and nearly 50% of patients will experience metastases during their lives. Anti EGFR targeted therapy is used for treatment of metastatic colorectal cancer. Approximately 30-50% of colorectal tumors are known to have a mutated (abnormal) KRAS gene. This mutated KRAS gene is predictive of resistance to EGFR therapies in advanced colorectal cancer. NCCN guidelines on colon cancer (Feb.2016) recommend that all patients with metastatic colorectal cancer should have tumor tissue genotyped for KRAS mutations.

• Colorectal cancer (CRC) remains the third leading cause of cancer-related deaths in the United States and nearly 50% of patients will experience metastases during their lives.
• Anti EGFR targeted therapy is used for treatment of metastatic colorectal cancer.
• Approximately 30-50% of colorectal tumors are known to have a mutated (abnormal) KRAS gene.
• This mutated KRAS gene is predictive of resistance to EGFR therapies in advanced colorectal cancer.
• NCCN guidelines on colon cancer (Feb.2016) recommend that all patients with metastatic colorectal cancer should have tumor tissue genotyped for KRAS mutations.

Result reported: Positive or Negative for KRAS mutations

Lincoln Labs KRAS Mutation Analysis offers:

• Turnaround time of 7-10 days
• Our highly qualified staff is accessible for any assistance regarding the tests.
• Broad coverage by most private and public insurance.

Specimen Requirement:

1. Formalin-fixed, paraffin-embedded (FFPE) tissues from routinely prepared small biopsies are practical and standard for KRAS mutation analysis.
2. Specimens are optimally fixed in 10% neutral-buffered formalin, optimal fixation time ranges from 6 to 24 hours.
3. Presence of tumor cells in the sample must be assessed by a pathologist.
4. Ratio of tumor cells to normal cells is crucial for adequate mutation testing and should be provide by the pathologist.
5. One H&E slide and 3-5 unstained slides (6-8microns ideal) are required for mutation testing.

Test Code:

ICD 10 Code:81275- KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis, variants in exon 2 (eg, codons 12 and 13)